Metabotropic Glutamate Receptors: Potential Drug Targets for Psychiatric Disorders

Akito Yasuhara*, a, Shigeyuki Chakib
a Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd
b Molecular Function and Pharmacology, Taisho Pharmaceutical Co., Ltd. Yoshino-cho, 1-403, kita-ku, Satitama 331-9530, Japan

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 1055
Abstract HTML Views: 452
PDF Downloads: 196
Total Views/Downloads: 1703
Unique Statistics:

Full-Text HTML Views: 294
Abstract HTML Views: 250
PDF Downloads: 147
Total Views/Downloads: 691

Creative Commons License
© Yasuhara and Chaki; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd. Yoshino-cho, 1-403, kita-ku, Satitama 331-9530, Japan; Tel: +81-48-669-3029; Fax: +81-48-652-7254; E-mail:


Metabotropic glutamate receptors (mGlu receptors) have emerged as new therapeutic targets for psychiatric disorders, such as schizophrenia, depression and anxiety with their regulatory roles in glutamatergic transmissions. To date, several ligands selective for each mGlu receptor have been synthesized, and pharmacological significances of these ligands have been demonstrated in animal models. Among them, mGlu2/3 receptor agonists have been proven to be effective for treating schizophrenia and anxiety disorders in clinical studies, which may prove utilities of mGlu receptor ligands for the treatment of psychiatric disorders. This article reviews recent advances in development of each mGlu receptor ligands and their therapeutic potential.

Keywords: Metabotropic glutamate receptor, mGlu, psychiatric disorder, drug target.